Literature DB >> 32572930

Expression level of lncRNA PVT1 in serum of patients with coronary atherosclerosis disease and its clinical significance.

W Quan1, P-F Hu, X Zhao, C-G Lianhua, B-R Batu.   

Abstract

OBJECTIVE: The purpose of this study was to detect the expression level of PVT1 in the serum of coronary artery disease (CAD) patients, and to explore the clinical significance of PVT1 in CAD. PATIENTS AND METHODS: A total of 200 CAD patients and 200 healthy controls in the same period were included. The serum level of PVT1 in every subject was detected. Then, the correlation between PVT1 level and Gensini score in CAD patients was analyzed by Spearman correlation test. Finally, multivariable Logistic regression test was conducted to assess risk factors influencing coronary atherosclerosis disease.
RESULTS: It was found that PVT1 was highly expressed in the serum of CAD patients and its level was correlated with Gensini score (r=0.761, p=0.023). Besides, multivariable Logistic regression test obtained that PVT1 was the risk factor influencing coronary atherosclerosis disease (crude OR = 2.074, 95% CI: 1.642-3.529; adjusted OR = 1.762, 95% CI: 1.382-2.096).
CONCLUSIONS: Serum level of PVT1 helps to distinguish mild and severe CAD. Meanwhile, PVT1 is an independent risk factor influencing the development of coronary atherosclerosis disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32572930     DOI: 10.26355/eurrev_202006_21531

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  Differential Expression of Long Noncoding RNAs in Patients with Coronary Artery Disease.

Authors:  Hamide Saygili; Ibrahim Bozgeyik; Onder Yumrutas; Erdal Akturk; Haydar Bagis
Journal:  Mol Syndromol       Date:  2021-08-26

2.  Long non-coding RNA Plasmacytoma variant 1 in acute ischemic stroke: association with disease risk, severity, and recurrence-free survival and relation with inflammatory cytokines.

Authors:  Liqiang Yu; Weihua Ling; Qi Fang
Journal:  Ir J Med Sci       Date:  2021-10-07       Impact factor: 2.089

3.  LncRNA APOA1-AS facilitates proliferation and migration and represses apoptosis of VSMCs through TAF15-mediated SMAD3 mRNA stabilization.

Authors:  Jixiang Wang; Ying Cai; Hui Lu; Fugeng Zhang; Junyi Zheng
Journal:  Cell Cycle       Date:  2021-08-12       Impact factor: 5.173

4.  Association of lncRNA PVT1 Gene Polymorphisms with the Risk of Essential Hypertension in Chinese Population.

Authors:  Rong Li; Xia Yu; Yang Chen; Mulun Xiao; Meiling Zuo; Yuanlin Xie; Zhousheng Yang; Dabin Kuang
Journal:  Biomed Res Int       Date:  2022-01-06       Impact factor: 3.411

5.  Small interfering RNA-induced silencing lncRNA PVT1 inhibits atherosclerosis via inactivating the MAPK/NF-κB pathway.

Authors:  Hong Du; Hui Zhang; Rong Yang; Li Qiao; Huiyu Shao; Xiaolin Zhang
Journal:  Aging (Albany NY)       Date:  2021-11-13       Impact factor: 5.682

6.  Knockdown of long non-coding RNA plasmacytoma variant translocation 1 relieves ox-LDL-induced endothelial cell injury through regulating microRNA-30c-5p in atherosclerosis.

Authors:  Geng Li; Wenxia Zong; Lei Liu; Juan Wu; Jing Pang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

7.  Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis.

Authors:  Jianping Tao; Yu Hu
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.298

8.  Long Non-Coding RNAs Might Regulate Phenotypic Switch of Vascular Smooth Muscle Cells Acting as ceRNA: Implications for In-Stent Restenosis.

Authors:  Alberto Arencibia; Fernando Lanas; Luis A Salazar
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.